Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis

References

• Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492–11. doi:10.1093/annonc/mdw217.
   PubMed Web of Science ®Google Scholar
• Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res. 2018;24(6):1260–70. doi:10.1158/1078-0432.CCR-17-2267.
   PubMed Web of Science ®Google Scholar
• Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4(1):7. doi:10.1038/s41541-019-0103-y.
   PubMed Web of Science ®Google Scholar
• Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125(9):3401–12. doi:10.1172/JCI80009.
   PubMed Web of Science ®Google Scholar
• Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24. doi:10.1038/s41577-019-0210-z.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar
• Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168–182. doi:10.1038/nri.2017.131.
   PubMed Web of Science ®Google Scholar
• Oladejo M, Paulishak W, Wood L. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Semin Cancer Biol. 2023;88:81–95. doi:10.1016/j.semcancer.2022.12.003.
   PubMed Web of Science ®Google Scholar
• Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: building a bridge over troubled waters. Cell. 2022;185(15):2770–2788. doi:10.1016/j.cell.2022.06.035.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–6. doi:10.1046/j.1445-2197.2003.02748.x.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: assessing risk of bias in a randomized trial. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V, editors. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane. www.training.cochrane.org/handbook.
   Google Scholar
• Lee WC, Wang HC, Hung CF, Huang P-F, Lia C-R, Chen M-F. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother. 2005;28(5):496–504. doi:10.1097/01.cji.0000171291.72039.e2.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C. et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non–small-cell lung cancer. J Clin Oncol. 2006;24(29):4721–30. doi:10.1200/JCO.2005.05.5335.
   PubMed Web of Science ®Google Scholar
• Powell A, Creaney J, Broomfield S, Van Bruggen I, Robinson B. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer. 2006;52(2):189–97. doi:10.1016/j.lungcan.2006.01.007.
   PubMed Web of Science ®Google Scholar
• Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y. et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007;30(7):749–761. doi:10.1097/CJI.0b013e3180de4ce8.
   PubMed Web of Science ®Google Scholar
• Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee J-H. et al. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother. 2008;31(1):72–80. doi:10.1097/CJI.0b013e31815ba792.
   PubMed Web of Science ®Google Scholar
• Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK. et al. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med. 2010;8(1):89. doi:10.1186/1479-5876-8-89.
   PubMedGoogle Scholar
• Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, Kiyohara Y, Yoshikawa S, Tanosaki R, Yamazaki N. et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep. 2012;28(4):1131–1138. doi:10.3892/or.2012.1956.
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Mackiewicz J, Wysocki PJ, Wiznerowicz M, Kapcinska M, Laciak M, Rose-John S, Izycki D, Burzykowski T, Karczewska-Dzionk A. et al. Long-term survival of high-risk melanoma patients immunized with a hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. Expert Opin Investig Drugs. 2012;21(6):773–783. doi:10.1517/13543784.2012.684753.
   PubMed Web of Science ®Google Scholar
• Chia WK, Wang WW, Teo M, Tai WM, Lim WT, Tan EH, Leong SS, Sun L, Chen JJ, Gottschalk S. et al. A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol. 2012;23(4):997–1005. doi:10.1093/annonc/mdr341.
   PubMed Web of Science ®Google Scholar
• Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ. et al. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell–based vaccine for refractory lung adenocarcinoma. J Immunother. 2013;36(8):442–50. doi:10.1097/CJI.0b013e3182a80237.
   PubMed Web of Science ®Google Scholar
• Florcken A, Kopp J, van Lessen A, van Lessen A, Movassaghi K, Takvorian A, Jöhrens K, Möbs M, Schönemann C, Sawitzki B. et al. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study. Hum Vaccin Immunother. 2013;9(6):1217–27. doi:10.4161/hv.24149.
   PubMed Web of Science ®Google Scholar
• Bapsy PP, Sharan B, Kumar C, Das RP, Rangarajan B, Jain M, Suresh Attili VS, Subramanian S, Aggarwal S, Srivastava M. et al. Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. Cytotherapy. 2014;16(2):234–244. doi:10.1016/j.jcyt.2013.11.013.
   PubMed Web of Science ®Google Scholar
• Xi HB, Wang GX, Fu B, Liu W-P, Li Y. Survivin and PSMA loaded dendritic cell vaccine for the treatment of prostate cancer. Biol Pharm Bull. 2015;38(6):827–35. doi:10.1248/bpb.b14-00518.
   PubMed Web of Science ®Google Scholar
• Mackiewicz J, Karczewska-Dzionk A, Laciak M, Kapcinska M, Wiznerowicz M, Burzykowski T, Zakowska M, Rose-John S, Mackiewicz A. Whole cell therapeutic vaccine modified with hyper-IL6 for combinational treatment of nonresected advanced melanoma. Medicine (Baltimore). 2015;94(21):e853. doi:10.1097/MD.0000000000000853.
   PubMed Web of Science ®Google Scholar
• Herbert GS, Vreeland TJ, Clifton GT, Greene JM, Jackson DO, Hardin MO, Hale DF, Berry JS, Nichol P, Yin S. et al. Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. Vaccine. 2018;36(23):3247–3253. doi:10.1016/j.vaccine.2018.04.078.
   PubMed Web of Science ®Google Scholar
• Gray BN, Walker C, Andrewartha L, Freeman S, Bennett RC. Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer. J Surg Oncol. 1989;40(1):34–7. doi:10.1002/jso.2930400109.
   PubMed Web of Science ®Google Scholar
• Hoover HC Jr., Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, Muenz LR, Hanna MG. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993;11(3):390–9. doi:10.1200/JCO.1993.11.3.390.
   PubMed Web of Science ®Google Scholar
• Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, Santarosa M, Sacco C, Talamini R, Gruppo Oncologico Clinico Coope T. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guèrin: five-year results of a prospective randomized study. Cancer. 1996;77(12):2560–6. doi:10.1002/(SICI)1097-0142(19960615)77:12<2560:AID-CNCR20>3.0.CO;2-P.
   PubMed Web of Science ®Google Scholar
• Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA. et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg. 1998;187(1):69–77; discussion 77–69. doi:10.1016/S1072-7515(98)00097-0.
   PubMed Web of Science ®Google Scholar
• Harris JE, Ryan L, Hoover HC Jr., Stuart RK, Oken MM, Benson AB, Mansour E, Haller DG, Manola J, Hanna MG. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: eastern cooperative oncology group study E5283. J Clin Oncol. 2000;18(1):148–57. doi:10.1200/JCO.2000.18.1.148.
   PubMed Web of Science ®Google Scholar
• Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q, Hua YP, Totsuka S, Liu SQ, Leong KW. et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004;10(5):1574–1579. doi:10.1158/1078-0432.CCR-03-0071.
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot CA, Vermorken JB, Hanna MG Jr., Verboom P, Groot M, Bonsel G, Meijer C, Pinedo H. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005;23(17–18):2379–87. doi:10.1016/j.vaccine.2005.01.015.
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M. et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11(11):4160–4167. doi:10.1158/1078-0432.CCR-05-0120.
   PubMed Web of Science ®Google Scholar
• Cho DY, Yang WK, Lee HC, Hsu D-M, Lin H-L, Lin S-Z, Chen C-C, Harn H-J, Liu C-L, Lee W-Y. et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg. 2012;77(5–6):736–744. doi:10.1016/j.wneu.2011.08.020.
   PubMed Web of Science ®Google Scholar
• Jie X, Hua L, Jiang W, Feng F, Feng G, Hua Z. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Cell Biochem Biophys. 2012;62(1):91–9. doi:10.1007/s12013-011-9265-6.
   PubMed Web of Science ®Google Scholar
• Carson WE 3rd, Unger JM, Sosman JA, Flaherty LE, Tuthill RJ, Porter MJ, Thompson JA, Kempf RA, Othus M, Ribas A. et al. Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res. 2014;2(10):981–7. doi:10.1158/2326-6066.CIR-14-0052.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Kotera Y, Aruga A, Takeshita N, Katagiri S, Ariizumi S-I, Takahashi Y, Yoshitoshi K, Takasaki K, Yamamoto M. Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. Hum Vaccin Immunother. 2014;10(4):970–6. doi:10.4161/hv.27678.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD. et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015;51(16):2321–2329. doi:10.1016/j.ejca.2015.07.035.
   PubMed Web of Science ®Google Scholar
• Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A. et al. Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases. Ann Surg Oncol. 2017;24(13):3991–4000. doi:10.1245/s10434-017-6072-3.
   PubMed Web of Science ®Google Scholar
• Yao Y, Luo F, Tang C, Chen D, Qin Z, Hua W, Xu M, Zhong P, Yu S, Chen D. et al. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunol Immunother. 2018;67(11):1777–1788. doi:10.1007/s00262-018-2232-y.
   PubMed Web of Science ®Google Scholar
• Vreeland TJ, Clifton GT, Hale DF, Chick RC, Hickerson AT, Cindass JL, Adams AM, Bohan PMK, Andtbacka RHI, Berger AC. et al. A phase IIb randomized controlled trial of the TLPLDC vaccine as adjuvant therapy after surgical resection of stage III/IV melanoma: a primary analysis. Ann Surg Oncol. 2021;28(11):6126–6137. doi:10.1245/s10434-021-09709-1.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker E-B, Grabbe S, Rittgen W, Edler L, Sucker A. et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17(4):563–570. doi:10.1093/annonc/mdj138.
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670–9. doi:10.1002/cncr.24429.
   PubMed Web of Science ®Google Scholar
• Caballero-Banos M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pagés M, Carrera G, Cuatrecasas M. et al. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer. 2016;64:167–174. doi:10.1016/j.ejca.2016.06.008.
   PubMed Web of Science ®Google Scholar
• Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW. et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res. 2011;17(13):4558–4567. doi:10.1158/1078-0432.CCR-10-3223.
   PubMed Web of Science ®Google Scholar
• George DJ, Nabhan C, DeVries T, Whitmore JB, Gomella LG. Survival outcomes of sipuleucel-T phase III studies: impact of control-arm cross-over to salvage immunotherapy. Cancer Immunol Res. 2015;3(9):1063–9. doi:10.1158/2326-6066.CIR-15-0006.
   PubMed Web of Science ®Google Scholar
• Skachkova OV, Khranovska NM, Gorbach OI, Svergun NM, Sydor RI, Nikulina VV. Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer. Exp Oncol. 2013;35:109–13.
   PubMedGoogle Scholar
• Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D’Andre SD. et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16(1):142. doi:10.1186/s12967-018-1507-6.
   PubMed Web of Science ®Google Scholar
• Hanna MG Jr., Hoover HC Jr., Vermorken JB, Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine. 2001;19(17–19):2576–82. doi:10.1016/S0264-410X(00)00485-0.
   PubMed Web of Science ®Google Scholar
• Doehn C, Richter A, Lehmacher W, Jocham D. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial. Folia Biol (Praha). 2003;49(2):69–73. doi:10.1016/S1569-9056(03)80393-7.
   PubMed Web of Science ®Google Scholar
• Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J. et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363(9409):594–599. doi:10.1016/S0140-6736(04)15590-6.
   PubMed Web of Science ®Google Scholar
• Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG. et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002;20(8):2058–2066. doi:10.1200/JCO.2002.08.071.
   PubMed Web of Science ®Google Scholar
• Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty LE, Richards JM, Bartolucci AA. et al. A phase III randomized, doúble-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer. 1995;75(1):34–42. doi:10.1002/1097-0142(19950101)75:1<34:AID-CNCR2820750108>3.0.CO;2-0.
   PubMed Web of Science ®Google Scholar
• Botrel TE, Clark O, Pompeo AC, Bretas FFH, Sadi MV, Ferreira U, Reis RBD. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. Int Braz J Urol. 2012;38(6):717–27. doi:10.1590/1677-553820133806717.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao JX, Liu YS, Xu B-L, Li D, Zhang X-Y, Li J-L, Liu J-L, Wang H-B, Wang Z-X. et al. Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis. BMJ Open. 2015;5(4):e006321. doi:10.1136/bmjopen-2014-006321.
   PubMed Web of Science ®Google Scholar
• Zhou L, Wang XL, Deng QL, Du Y-Q, Zhao N-Q. The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis. Sci Rep. 2016;6:32020. doi:10.1038/srep32020.
   PubMed Web of Science ®Google Scholar
• Chen C, Ma Yh, Zhang Yt, Zhang F, Zhou N, Wang X, Liu T, Li Y-M. Effect of dendritic cell–based immunotherapy on hepatocellular carcinoma: a systematic review and meta-analysis. Cytotherapy. 2018;20(8):975–89. doi:10.1016/j.jcyt.2018.06.002.
   PubMed Web of Science ®Google Scholar
• Han CL, Yan YC, Yan LJ, Meng G-X, Yang C-C, Liu H, Ding Z-N, Dong Z-R, Hong J-G, Chen Z-Q. et al. Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades. J Cancer Res Clin Oncol. 2023;149(4):1425–1441. doi:10.1007/s00432-022-04008-y.
   PubMed Web of Science ®Google Scholar
• Lv L, Huang J, Xi H, Zhou X. Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: a meta-analysis of randomized controlled trials. Int Immunopharmacol. 2020;83:106336. doi:10.1016/j.intimp.2020.106336.
   PubMed Web of Science ®Google Scholar
• Shamshiripour P, Nikoobakht M, Mansourinejad Z, Ahmadvand D, Akbarpour M. A comprehensive update to dendritic cell therapy for glioma: a systematic review and meta-analysis. Expert Rev Vaccines. 2022;21(4):513–31. doi:10.1080/14760584.2022.2027759.
   PubMed Web of Science ®Google Scholar
• Dafni U, Martin-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, Coukos G, Zaman K, Sarivalasis A, Kandalaft LE. et al. Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: a 20-year systematic review and meta-analysis. Eur J Cancer. 2021;142:63–82. doi:10.1016/j.ejca.2020.10.014.
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA, Donehower RC, Jaffee EM. et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36(7):382–389. doi:10.1097/CJI.0b013e31829fb7a2.
   PubMed Web of Science ®Google Scholar
• Scholz M, Yep S, Chancey M, Kelly C, Chau K, Turner J, Lam R, Drake C. Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. Immunotargets Ther. 2017;6:11–16. doi:10.2147/ITT.S122497.
   PubMed Web of Science ®Google Scholar
• De Keersmaecker B, Claerhout S, Carrasco J, Bar I, Corthals J, Wilgenhof S, Neyns B, Thielemans K. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. J Immunother Cancer. 2020;8(1):e000329. doi:10.1136/jitc-2019-000329.
   PubMed Web of Science ®Google Scholar